- Home
- EXTR vs RCKT Comparison
EXTR vs RCKT Comparison
Compare EXTR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXTR
- RCKT
- Stock Information
- Founded
- EXTR 1996
- RCKT 1999
- Country
- EXTR United States
- RCKT United States
- Employees
- EXTR N/A
- RCKT N/A
- Industry
- EXTR Telecommunications Equipment
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- EXTR Telecommunications
- RCKT Health Care
- Exchange
- EXTR Nasdaq
- RCKT Nasdaq
- Market Cap
- EXTR 2.2B
- RCKT 326.4M
- IPO Year
- EXTR 1999
- RCKT N/A
- Fundamental
- Price
- EXTR $18.45
- RCKT $2.59
- Analyst Decision
- EXTR Strong Buy
- RCKT Buy
- Analyst Count
- EXTR 7
- RCKT 13
- Target Price
- EXTR $18.57
- RCKT $18.50
- AVG Volume (30 Days)
- EXTR 1.1M
- RCKT 4.5M
- Earning Date
- EXTR 08-06-2025
- RCKT 08-04-2025
- Dividend Yield
- EXTR N/A
- RCKT N/A
- EPS Growth
- EXTR N/A
- RCKT N/A
- EPS
- EXTR N/A
- RCKT N/A
- Revenue
- EXTR $1,089,717,000.00
- RCKT N/A
- Revenue This Year
- EXTR $3.47
- RCKT N/A
- Revenue Next Year
- EXTR $7.79
- RCKT N/A
- P/E Ratio
- EXTR N/A
- RCKT N/A
- Revenue Growth
- EXTR N/A
- RCKT N/A
- 52 Week Low
- EXTR $10.10
- RCKT $2.19
- 52 Week High
- EXTR $19.24
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- EXTR 70.37
- RCKT 31.97
- Support Level
- EXTR $17.59
- RCKT $2.56
- Resistance Level
- EXTR $18.18
- RCKT $2.70
- Average True Range (ATR)
- EXTR 0.44
- RCKT 0.20
- MACD
- EXTR 0.06
- RCKT 0.10
- Stochastic Oscillator
- EXTR 92.86
- RCKT 10.22
About EXTR Extreme Networks Inc.
Extreme Networks Inc provides cloud networking solutions and industry services and support. Extreme designs, develops, and manufactures wired, wireless, and software-defined wide area-network (SD- WAN) infrastructure equipment, software and cloud-based network management solutions. The company's cloud solution is a single platform that offers unified network management of wireless access points, switches, and SD-WAN. The company operates in a single segment which develops and markets network infrastructure equipment. Roughly half of the firm's revenue is generated in the Americas, with the rest coming from Europe, the Middle East, Africa, and Asia-Pacific.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.